What Should You Do When Quality System Certificates Are Inconsistent for Medical Device Registration in Japan?

Answer: For the question "What should you do when quality system certificates are inconsistent for medical device registration in Japan?", a manufacturer should first confirm the target country, the product risk class, the applicable regulatory pathway and the documentation already available, and then assess the technical file, quality system, labeling and instructions for use, local agent arrangements, clinical evidence and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission, so that unclear classification, incomplete documentation or ambiguous authorization arrangements do not unnecessarily extend the project timeline.

For Chinese medical device manufacturers, the more reliable approach is to complete the product classification and documentation gap assessment first, and only then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused. Registration in a target market typically affects the technical file, authorized representative, importer cooperation, label language, quality system certification and subsequent change maintenance at the same time. If the project is driven only by the question of "which documents to submit," deficiencies or rework are likely to arise in model coverage, evidence chain consistency, label claims and certificate control. AIMEILI recommends planning this issue within a GHWP member state and multi-country access strategy, using one reusable core technical file to support localization in different markets, rather than recreating documentation on an ad hoc basis in each country.

This content is compiled from the AIMEILI regulatory practice question bank, the medical device international registration knowledge base and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country regulator and the manufacturer's actual product documentation.

Key Summary

Regarding the question "What should you do when quality system certificates are inconsistent for medical device registration in Japan?", a manufacturer should first confirm the target country, product risk class, applicable regulatory pathway and existing documentation base, and then assess the technical file, quality system, labeling and instructions for use, local agent, clinical evidence and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission, so that unclear classification, documentation or authorization arrangements do not prolong the project.

For Chinese medical device manufacturers, the more reliable approach is to complete the product classification and documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused. Registration in a target market usually affects the technical file, authorized representative, importer cooperation, label language, quality system certification and subsequent change maintenance at the same time. If work is driven only by "which documents to submit," deficiencies or rework are likely in model coverage, evidence chain consistency, label claims and certificate control.

AIMEILI recommends planning this issue within a GHWP member state and multi-country access strategy, using one reusable core technical file to support localization in different markets, rather than recreating documentation for each country on a case-by-case basis.

Applicable Scenarios and Core Questions

Companies searching for "What should you do when quality system certificates are inconsistent for medical device registration in Japan?" are usually not looking for a conceptual explanation. They want to judge whether existing documentation can support registration in the target market, whether a local agent or authorized representative is required, why the timeline is being extended, and which issues may affect the launch plan. Behind this question there are often simultaneous considerations of product classification, registration pathway, evidence chain, label localization and post-market maintenance responsibility.

If a company intends to enter several GHWP member states at the same time, or markets in Southeast Asia, the Middle East and Latin America, answering the process for one country alone is not sufficient. A more valuable approach is to first develop reusable versions of the core technical file, quality system certification, performance verification, clinical evidence and labeling and instructions for use, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

A manufacturer should first confirm the intended use, mechanism of action, use scenario, method and duration of body contact, whether the device is sterile, whether it is active, and whether it contains software or has IVD attributes, and then determine the risk class and submission pathway. Once the pathway decision is wrong, the subsequent translation, notarization, authorization, testing and supplementary documentation will all move in the wrong direction.

For a target market project, the applicant entity and the boundaries of local responsibility must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles import and post-market incidents, who triggers changes, and who maintains the documentation for certificate renewal. If these issues are handled vaguely only in a commercial contract, market control can easily be affected later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, basis for risk classification, ISO 13485 or applicable quality system certification, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labeling and instructions for use, authorization documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. Labeling claims, the models covered by test reports, the scope of application of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must support one another. Regulators focus on whether the device is safe, effective and traceable for the intended use, not on how many documents a company has uploaded.

Common Errors

The most common problem is treating the registration project as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting domestic NMPA documentation after direct translation, without reorganizing the evidence according to the target market pathway.
• Listing too many models and specifications, while test reports, clinical evidence or labels cover an insufficient scope.
• Selecting a local agent purely on the basis of sales cooperation, without clarifying regulatory responsibility, certificate control and post-market maintenance obligations.
• Inconsistency between labels, instructions for use, promotional materials and registration documentation claims, leading to deficiency notices or post-market compliance risk.
• Failure to plan multi-country documentation reuse in advance, resulting in duplicated preparation for each country and inflated cost and timelines.

Manufacturer Preparation Checklist

Before starting the project, manufacturers are advised to confirm the documentation base using an internal checklist, so that critical evidence gaps are not discovered only after submission.

• Compile the target product list, model and specification matrix, and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management, clinical evaluation and English instructions for use.
• Confirm the responsibilities, fees, certificate control and exit mechanism of the local agent or authorized representative.
• Establish a gap assessment table for the target country, specifying what needs additional testing, translation, notarization or supplementary declarations.

AIMEILI Perspective

AIMEILI advises manufacturers not to treat target market registration as a one-off document submission, but to manage it as an overseas market access program. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first, and then converting it according to national requirements, is usually faster and more stable than supplementing documentation on a country-by-country basis, and it also supports subsequent changes and certificate renewals more effectively.

From a project management perspective, three things should be controlled in advance: first, product classification and pathway determination; second, the consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, the project may still encounter repeated rounds of deficiency responses, agent communication and post-market maintenance issues, no matter how extensive the documentation appears to be.

Frequently Asked Follow-Up Questions

Can domestic documentation be used directly for target market registration?

Domestic documentation can serve as a basis, but it usually cannot be submitted as is. Manufacturers need to adjust the documentation structure, language, labels, authorization documents and evidence chain in accordance with local regulatory requirements.

When is the best time to start the gap assessment?

It is advisable to start immediately after confirming the target market and the product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent usually participates in registration communication, changes, certificate renewal and post-market incident handling. If responsibilities are unclear, this affects certificate control and the stability of the subsequent market position.

Project Execution Recommendations

When executing this type of registration project, manufacturers should establish a project ledger that manages the product list, model and specification information, registration pathway, documentation owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This allows documentation gaps to be identified promptly and helps management judge whether the project will affect the launch plan.

For companies that already have registration bases in multiple countries, an evidence reuse matrix should also be established to clarify which documentation can serve as core evidence and which documentation must be reissued or supplemented with explanations according to national requirements. Labeling and instructions for use, clinical evaluation, risk management, performance verification and quality system certificates must in particular be kept consistent in version.

• Confirm the target market and product list.
• Complete the risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify the local agent and certificate control arrangements.
• Track translation, notarization, testing and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators typically examine whether the manufacturer name, manufacturing site, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope covered by the ISO 13485 certificate does not match the product being submitted, or if the manufacturing site, model and specification information, or instructions for use version is inconsistent with the test reports, the manufacturer may be asked for supplementary explanations even if a large volume of documentation has been prepared.

Before submission, manufacturers should establish an evidence consistency checklist that maps product name, model and specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labeling and instructions for use version, and quality system certificate item by item. This action may appear basic, but it can significantly reduce the probability of deficiency notices, particularly for projects involving simultaneous submissions in multiple GHWP member states or for multiple product families.

Localization and Agent Responsibilities

Target market registration projects usually involve arrangements for a local agent, authorized representative, importer or registration holder. Manufacturers need to confirm in advance whether the local partner is responsible only for submitting documentation, or also for regulatory communication, certificate maintenance, post-market incident reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and the stability of the subsequent market position.

Labels, instructions for use and authorization documents also cannot simply be translated. Manufacturers should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization is to transform reusable evidence into a submission structure acceptable in the target country, rather than writing a separate, isolated set of documentation.

Post-Market Maintenance and Long-Term Planning

Registration approval does not mean the compliance work is finished. Manufacturers also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest substantial effort in obtaining the certificate but neglect post-market maintenance. If a manufacturing site change, model expansion, instructions for use update or agent replacement then occurs, the certificate can easily become disconnected from actual market sales.

AIMEILI recommends managing this issue within an annual international registration plan: first establish target market priorities, then build a reusable documentation package and a country gap list, and finally schedule submission, deficiency response, post-market maintenance and certificate renewal milestones. The value of this approach is not only improved efficiency for registration in a single country; more importantly, it enables a manufacturer to build a replicable overseas compliance capability and reduce the cost of starting from scratch every time it enters a new market.

Further Reading

• Previous: How Should Performance Verification Documentation Be Prepared for Medical Device Registration in Japan?
• Next: How Should Registration Documentation Be Prepared for Medical Device Registration in the European Union?

Recommended reading:

• How Should a Local Agent Be Selected for Medical Device Registration in Brazil?
• How Should Authorized Representative Responsibilities Be Divided for Medical Device Registration in Brazil?
• Why Does the Medical Device Registration Timeline in Brazil Become Extended?
• What Are the Common Reasons for Documentation Deficiency Notices in Brazilian Medical Device Registration?
• How Should Post-Market Surveillance Be Conducted for Medical Device Registration in Brazil?
• When Do Registration Changes Need to Be Filed for Medical Device Registration in Brazil?

Return to the FAQ Center. News and Insights. Contact AIMEILI.

Content Review and Applicability Boundaries

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team. Source principle: priority is given to official regulatory authorities, international organizations, standards organizations and publicly available regulatory information; industry media and project experience are used only as supporting judgment.

Applicability boundaries: this article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country regulator, testing conclusions or legal opinions.